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Abstract
Patients with lung cancer often present with metastatic disease and therefore have a very poor
prognosis. The recent discovery of several novel ROS receptor tyrosine kinase molecular
alterations in non-small-cell lung cancer (NSCLC) presents a therapeutic opportunity for the
development of new targeted treatment strategies. Here, we report that the NSCLC-derived fusion
CD74-ROS, which accounts for 30% of all ROS fusion kinases in NSCLC, is an active and
oncogenic tyrosine kinase. We found that CD74-ROS expressing cells were highly invasive in
vitro and metastatic in vivo. Pharmacological inhibition of CD74-ROS kinase activity reversed its
transforming capacity by attenuating downstrream signaling networks. Using quantitative
phosphoproteomics, we uncovered a mechanism by which CD74-ROS activates a novel pathway
driving cell invasion. Expression of CD74-ROS resulted in the phosphorylation of the extended
synaptotagmin-like protein E-Syt1. Elimination of E-Syt1 expression drastically reduced
invasiveness both in vitro and in vivo without modifying the oncogenic activity of CD74-ROS.
Furthermore, expression of CD74-ROS in non-invasive NSCLC cell lines readily confered
invasive properties that paralleled the acquisition of E-Syt1 phosphorylation. Taken together, our
findings indicate that E-Syt1 is a mediator of cancer cell invasion and molecularly define ROS
fusion kinases as therapeutic targets in the treatment of NSCLC.
Introduction
ROS is an orphan receptor tyrosine kinase (RTK) proto-oncogene expressed in glioma and
lung cancer (1) whose function in cancer remains unknown. Chromosomal rearrangements
of the c-ROS locus that create fusion kinases have been reported in gliomas (1%) (2, 3) and
cholangiocarcinomas (8.7%) (4) suggesting that ROS fusion kinases may represent a new
therapeutic target.
Lung cancer is the leading cause of cancer-related deaths in the US and worldwide (5).
NSCLC is a clinically challenging disease to control and in recent years, our understanding
of the molecular events driving NSCLC formation and maintenance has increased
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dramatically, leading to changes in the treatment of this disease where targeted therapy
against activated kinases can be an effective and successful approach (6). The majority of
NSCLC patients are diagnosed with advanced stage that spread beyond the primary site and
approximately half of patients have metastatic (stage IV) disease at diagnosis thus limiting
treatment options to palliative management (7). The extent of the invasive component seen
in lung cancer is strongly associated with clinical outcomes. Patients presenting with non-
invasive tumors, which are biologically indolent, have a much better prognosis than those
with adenocarcinomas, a highly invasive tumor with increased risk of metastatic disease and
death. As invasion is an early step of cancer metastasis, a detailed understanding of the
molecular mechanisms of tumor cell invasion is required to provide new treatment options.
Using split FISH BAC assays to screen for ROS gene rearrangements, two groups recently
reported that approximately 1.4% of NSCLCs harbor ROS rearrangements, defining a new
genetic subtype of NSCLC (8, 9). The authors identified known and novel fusion partners
for ROS and to date, ROS fusion partners are TPM3, SDC4, SLC34A2, LRIG3, CD74 and
EZR with the most common event reported being CD74-ROS. With an estimated >200,000
new cases of lung cancer per year in the U.S. alone, there are approximately 3,000 new
ROS-rearranged NSCLC tumors per year (10). In both studies, the authors found that ROS
fusion-positive patients tend to be younger, never-smokers with a histologic diagnosis of
adenocarcinoma presenting with stage IV disease (8, 9).
Here we report that the NSCLC ROS fusion kinase CD74-ROS, similar to FIG-ROS, is
highly oncogenic. We provide evidence that pharmacological inhibition of ROS fusion
kinases produces anti-tumorigenic effects and we observed that CD74-ROS expressing cells
are highly invasive compared to FIG-ROS positive cells. We uncovered the molecular
mechanism driving this invasiveness using phosphoproteomics. We report that E-Syt1, an
extended synaptotagmin-related C2-domain containing protein, is highly phosphorylated
(Y993) in CD74-ROS expressing cells and that elimination of E-Syt1 expression abolishes
invasion of these cells both in vitro and in vivo. Our results uncover a function for E-Syt1 in
the transduction of invasive signals in cancer cells.
Materials and Methods
ROS fusion constructs, retrovirus production and transformation assays
The various ROS fusion constructs depicted in Fig. 1A were assembled using standard
molecular biology techniques as detailed in Supplementary Materials and Methods. The
cDNAs were expressed using the pLXSN retrovirus system (11) produced in Phoenix cells
(Gary Nolan, Stanford University) and used to infect Rat1 or NSCLC cells as described
(12). Monoclonal cell lines were isolated by selecting individual G418-resistant colonies and
assayed for density saturation growth, colony formation assays, growth in soft agar and
migration assays as described in detail in Supplementary Materials and Methods and
elsewhere (2).
Immunoprecipitation and immunoblotting
Target proteins were immunoprecipitated as follows: cells were lysed by resuspension in
lysis buffer (2). The lysates were incubated for 10 min on ice and the cell debris was
pelleted by centrifugation. The indicated antibodies were added to the supernatants along
with protein A/G-agarose beads (Invitrogen), and binding was allowed to proceed for 16 hr
at 4°C. The bead-bound protein complexes were washed before being subjected to SDS-
PAGE. Western blots were performed as follows: cell lysates were prepared as above and
total cell lysates were separated on polyacrylamide gels and transferred to a PVDF
membrane (Immobilon P, Millipore). Blots were blocked for 1 hour and primary antibodies
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were added to the blocking solution and incubated overnight at 4°C on a shaker. Blots were
washed several times and then the secondary antibodies were incubated for 1 hour followed
by several washes and enhanced chemiluminescence (ECL) reactions were performed as
described by the manufacturer (Western Lightning Kit, Perkin Elmer).
Growth in immunocompromised mice
All animal procedures were performed in accordance with Tufts University’s
recommendations for care and use of animals and were maintained and handled under
protocols approved by IACUC. Assays of tumorigenicity in immunocompromised mice
were performed as previously described (13). Briefly, 5×106 of the indicated cells were
injected subcutaneously in PBS or matrigel and tumor growth was monitored over time
using caliper measurements.
Sample preparation, phosphopeptide immunoprecipitation, labeling and MS
Clonal Rat1 cells expressing the indicated ROS fusion proteins were incubated for 24 h in
serum-free media then lysed and differentially labeled with 8plex. Instrumentation settings
and reagents are described in details in the Supplementary Materials and Methods.
RNA interference
RNAi-mediated knockdown was performed using the lentiviral pSicoR-pgkPURO vector
system (14). Five short hairpin sequences were designed using the pSICOLIGOMAKER 1.5
software against rat E-Syt1 mRNA sequence and cloned, along with a scrambled sequence
control shRNA, into pSicoR-pgkPURO according to established protocols (http://
web.mit.edu/jacks-lab/protocols/pSico.html). Lentiviruses were prepared as described
elsewhere (14) and used to infect Rat1 CD74-ROS cells followed by selection with
puromycin (4 μg/mL). Individual clones were selected and expanded for analysis.
Statistical analysis
Statistical analyses were performed using the two-tailed, unpaired Student’s t test in Prism
5.0 (GraphPad Software).
Results
Oncogenic activity of ROS fusion kinases
We have previously demonstrated the oncogenic activity of FIG-ROS both in vitro and in
vivo (2, 3, 15). Here, we sought to validate the oncogenic activities of the newly described
NSCLC-derived CD74-ROS and SLC34A2-ROS fusion kinases. Using standard molecular
biology techniques, we recreated the CD74-ROS and two isoforms of the SLC34A2-ROS
fusion cDNAs and expressed these, along with FIG-ROS, in immortalized, non-transformed
Rat1 cells (Fig. 1A). After selection, clonal isolates were screened for expression levels and
kinase activity by immunoblots (Supplementary Fig. 1A) and three clones for each
constructs demonstrating similar expression levels and kinase activity were chosen for
transformation studies.
Expression of kinase active (WT) forms of FIG-ROS and CD74-ROS but not SLC34A2-
ROS proteins in Rat1 cells led to a drastic change in cellular morphology, which correlated
with their capacity to reach elevated saturation densities (Fig. 1B). Expression of active
CD74-ROS and FIG-ROS can overcome saturation-dependent growth arrest in Rat1 cells in
a focus formation assay. Foci were not observed with their kinase-inactive versions (KM),
vector (pLXSN) control or from the SLC34A2-ROS expressing cells (Fig. 1C and
Supplementary Fig. 1B). Cells expressing FIG-ROS-WT and CD74-ROS-WT are capable of
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sustained growth in an anchorage-independent environment whereas control cell lines and
cells expressing SLC34A2-ROS were incapable of growing under the same conditions (Fig.
1D and Supplementary Fig. 1C). To further examine their tumorigenicity, FIG-ROS and
CD74-ROS expressing cells were injected subcutaneously into immunocompromised mice.
FIG-ROS or CD74-ROS expressing cells developed tumors with a relatively short latency
(20–25 days) whereas no tumors were found in mice injected with cells expressing kinase-
inactive versions, pLXSN vector control or SLC34A2-ROS (Fig. 1E). Finally, we
demonstrated that CD74-ROS and FIG-ROS are capable of conferring enhanced migratory
potential to cells in an in vitro “scratch” assay (Supplementary Fig. 1D). Together, these
results demonstrate that FIG-ROS and CD74-ROS fusion kinases are oncoproteins.
Surprisingly, SLC34A2-ROS lacks transformation potential under identical circumstances,
suggesting perhaps that localization or signaling differences between SLC34A2-ROS and
FIG-ROS or CD74-ROS might be responsible for this observation.
Distinct cellular localization and signaling of ROS fusion kinases
CD74 and SLC34A2 are integral plasma membrane-spanning proteins. To determine the
cellular localization of CD74-ROS and SLC34A2-ROS, we performed indirect
immunofluorescence microscopy. Unlike FIG-ROS, which is a Golgi apparatus-associated
oncoprotein (2), the staining pattern of CD74-ROS and SLC34A2-ROS in Rat1 cells
advocate that these fusion kinases reside within the plasma membrane (Supplementary Fig.
2A). Furthermore, CD74-ROS and SLC34A2-ROS co-localized with the plasma membrane
marker epidermal growth factor receptor (EGFR). These results were validated by
subcellular fractionation studies that demonstrated that CD74-ROS and SLC34A2-ROS
proteins are present within plasma membrane fractions (Supplementary Fig. 2B).
Next, we ascertained whether these differences in localization affect the signaling profiles of
these kinases. Studies on ROS signaling demonstrated that ROS activates SHP-1 and SHP-2,
ERK1/2, IRS-1, PI3K, AKT and STAT3 signaling pathways (1). We performed western blot
analysis using phospho-specific antibodies against known ROS target signaling pathways
and showed that expression of FIG-ROS and CD74-ROS but not their kinase-inactive
counterparts nor SLC34A2-ROS activates the MAPK, SHP-2, STAT-3, Akt and mTORC1
pathways (Supplementary Fig. 3A–D). These results demonstrate that although SLC34A2-
ROS localized to the plasma membrane and is an active kinase, it is incapable of stimulating
signaling pathways that are common between FIG-ROS and CD74-ROS and known to be
oncogenic.
ROS fusion kinases are potential therapeutic targets
The amino acid sequence of the kinase domain of ROS is highly homologous to that of the
ALK RTK. We hypothesized that ROS fusion kinase-expressing cells would be sensitive to
the tool compound ALK inhibitor NVP-TAE684 (16) and the clinical compound Crizotinib
(PF-02341066) (17). Treatment of FIG-ROS or CD74-ROS cells with NVP-TAE684 led to a
dose dependent reduction in growth with IC50 values of less than 10 nM (Fig. 2A). This
reduction in growth parallels the inhibition of the kinase activity of ROS fusion kinases
(Supplementary Fig. 4A) and an attenuation of their signaling networks (Fig. 2B). To
validate ROS fusion kinases as genuine therapeutic targets, we evaluated the activity of
NVP-TAE684 on the transformation capacity of ROS fusion kinases. We performed
experiments on cell growth, saturation-dependent growth inhibition and anchorage-
independent growth assays on FIG-ROS and CD74-ROS expressing Rat1 cells in the
presence of vehicle control or 10 nM of NVP-TAE684 (Fig. 2C-E and Supplementary Fig.
4B) and showed that inhibition of ROS fusion kinases has drastic anti-cancer effects on
these cells. Treatment of cells expressing FIG-ROS or CD74-ROS with the clinically
available drug Crizotinib led to a dose dependent reduction in growth with IC50 values of
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less than 5 nM (Supplementary Fig. 4C). Finally, we evaluated the effects of a recently
described ROS-specific kinase inhibitor; KIST301080 (18, 19) and determined that the
optimal concentrations of this compound for ROS kinase inhibition is relatively high (10–50
μM) (Supplementary Fig. 5A–E), and was not pursued further. Taken together, these results
demonstrate that small-molecule based inhibition of ROS fusion kinase activity with an
inhibitor is a potent anti-oncogenic treatment that can reverse the transformed phenotype of
these cancer cells.
CD74-ROS expressing cells are highly invasive and metastatic
Histopathological analysis of FIG-ROS and CD74-ROS Rat1 xenograft tumors revealed that
CD74-ROS tumors are more invasive than those derived from FIG-ROS, capable of
infiltrating through the parietal peritoneum, extraperitoneal fat and muscle layers (Fig. 3A)
and observed to metastasized to lymph nodes (Fig. 3B). This difference in invasiveness
between FIG-ROS and CD74-ROS is also observed in vitro in a matrigel Boyden chamber
invasion assay (Fig. 3C). CD74-ROS expressing cells are 15.8 fold more invasive than
vector control cells whereas FIG-ROS expressing cells are 1.6 fold more invasive than
control cells. These results demonstrate that expression of CD74-ROS in Rat1 cells triggers
a mechanism that renders cells highly invasive and metastatic.
Quantitative phosphotyrosine profiling of FIG-ROS, CD74-ROS and SLC34A2-ROS
expressing Rat1 cells
We surmised that the observed difference in invasiveness between FIG-ROS and CD74-
ROS expressing cells might be due to potential differences in the activation of tyrosine
phosphorylation signaling pathways. We performed a quantitative phosphoproteomics
analysis across kinase active and kinase dead versions of FIG-ROS, CD74-ROS, SLC34A2-
ROS and vector control Rat1 cells. Quantitative analysis of 3 biological replicates yielded
89 phosphotyrosine peptides identified and quantified in 2 or more analyses. The mean ratio
for each peptide was calculated along with the standard deviation and coefficient of
variation across biological replicates (the complete dataset is summarized in Table S1). To
identify the phosphotyrosine sites that are specifically associated with CD74-ROS-WT
expressing Rat1 cells, and thus the invasive phenotype, we compared the relative iTRAQ
intensities of signals observed in the FIG-ROS-WT and the CD74-ROS-WT expressing Rat1
cells. Of the 89 phosphotyrosine peptides, 35 were significantly different with an associated
p value of ≤0.05 (Fig. 4A). This list of significantly different tyrosine phosphorylated
peptides was then sorted based on those with the greatest relative intensity in the CD74-
ROS-WT expressing cells. E-Syt1 phosphorylation on site pY993 was found to be the most
highly increased in CD74-ROS-WT compared to FIG-ROS-WT expressing cells (Fig.
4B,C). The observed increase in tyrosine phosphorylation of E-Syt1 was validated by
immunoprecipitation western using lysates from vector control, FIG-ROS-WT and CD74-
ROS-WT expressing Rat1 cells (Fig. 4D). The increase in phosphorylation at pY993 appears
to be due to an increase in the upstream signaling pathways, as the E-Syt1 protein levels
remains constant across pLXSN, CD74-ROS-WT and FIG-ROS-WT cells (Fig. 5A).
E-Syt1 mediates CD74-ROS-triggered invasiveness
To solidify the role of E-Syt1 in conferring increased invasiveness in CD74-ROS expressing
cells, we used RNAi to knock down the expression of E-Syt1 in these cells. Two potent E-
Syt1 shRNAs and a scrambled sequence control shRNA were chosen to create clonally
selected cell lines from Rat1 cells expressing FIG-ROS, CD74-ROS and from vector control
Rat1 cells (Supplementary Fig. 6A,B). We performed invasion assays and demonstrated that
E-Syt1 knockdown CD74-ROS expressing cells no longer invade in vitro (Fig. 5B) and in
vivo when grown subcutaneously as xenograft tumors (Fig. 5C). These results demonstrate
that expression of CD74-ROS confers invasiveness to cells through the activity of E-Syt1.
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We confirmed that the loss of invasiveness was not due to a loss of oncogenic activity from
CD74-ROS by performing growth curves, colony formation assays and growth in soft agar
assays and growth of xenograft using CD74-ROS cells and E-Syt1 knockdown cells. We
demonstrated that elimination of E-Syt1 does not affect the ability of CD74-ROS to
transform cells (Supplementary Fig. 6C–G). The effects of eliminating E-Syt1 expression on
the activation of ROS signaling networks parallel those on cell transformation, that is, loss
of E-Syt1 had no effect on the signaling of MAPK, SHP-2, STAT-3, Akt and mTORC1
pathways (Supplementary Fig. 7A–D). These results demonstrate that eliminating the
expression of E-Syt1 in CD74-ROS expressing cells abolished the invasiveness of these
cells without affecting the oncogenic transformation capacity of CD74-ROS.
To validate these results in a model of NSCLC, CD74-ROS was expressed in three non-
invasive NSCLC cell lines (NCI-H1915, NCI-H2009 and NCI-H1755) and three
independent clones for each construct were selected for in vitro invasion studies (Fig. 6A).
Expression of CD74-ROS in the H1915, H1755 and H2009 lines induced invasion 18.4,
13.3 and 3.5 fold over control vector cells respectively (Fig. 6B). Expression of kinase
inactive CD74-ROS was incapable of conferring invasive properties to the same cells.
Similar to the Rat1 cells, the acquisition of an invasive phenotype parallel the appearance of
phosphorylated E-Syt1 in CD74-ROS expressing cells (Fig. 6A). Lastly, we ascertained the
ROS canonical signaling networks in NSCLC lines stably expressing CD74-ROS. Unlike
the Rat1 cell model, only SHP-2 is activated in all three lines whereas the MAPK, mTORC1
and STAT-3 pathways are moderately engaged or absent (Fig. 7A,B).
Discussion
In recent years, our understanding of the molecular events driving NSCLC formation and
maintenance has increased dramatically, fueling paradigm shifts in treatment of this disease.
The subdivision of NSCLC into clinically relevant molecular subsets according to specific
driver mutations led to seminal trials for NSCLC patients with mutant EGFR treated with
gefitinib that resulted in a prolonged progression-free survival and an improved quality of
life when compared to patients given only cytotoxic chemotherapy (20, 21). Similarly, the
EML4-ALK fusion kinase defines a second clinically actionable oncogenic driver mutation
in NSCLC that yielded a similarly impressive response rate (22). Two recent large-scale
screens for ROS fusion kinases in NSCLCs have revealed that 1.4% of NSCLC have
rearrangements at the c-ROS locus, which defines a new molecular subclass of NSCLC. Of
the ROS fusion positive tumors, 30% are known to harbor a recurrent translocation t(5;6)
(q32;q22), which creates the CD74-ROS fusion kinase described herein.
The advent of large-scale molecular genetic studies of cancer such as the ones described
above, continues to uncover a significant number of mutations in various genes. Although
the results of many these events appear a priori to be oncogenic, there is a requirement for
empirical validation of their oncogenicity in controlled paradigms. Our studies demonstrate
that CD74-ROS, like FIG-ROS, is a potent oncoprotein capable of readily transforming
fibroblast cells through activation of the canonical signaling pathways SHP-2, STAT-3 and
MAPK. Surprisingly, in the same context, the SLC34A2-ROS fusion kinase was unable to
activate these pathways and is incapable of transformation even though its tyrosine kinase
activity is comparable to that of CD74-ROS and FIG-ROS. This lack of oncogenicity for
SLC34A2-ROS is similar to results recently reported by Takeuchi and colleagues (9) and
suggests that cellular transformation by SLC34A2-ROS might be context dependent.
Our results suggest that CD74-ROS represents a new target for the treatment of NSCLC.
The high degree of homology between the kinase domains of ALK and ROS predicts that
ALK inhibitors would exert inhibition of ROS. Indeed, we demonstrated that the ALK
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inhibitor tool compound NVP-TAE684 and the clinically available ALK/MET inhibitor
Crizotinib displayed low IC50 values against ROS fusion kinases expressing cells and
showed that pharmacological inhibition of ROS fusion kinases results in compelling anti-
cancer effects. In fact, while this manuscript was under review, our results were validated in
a NSCLC patient afflicted with a ROS fusion kinase positive tumor who displayed a
remarkable response to Crizotinib treatment (8).
So far, CD74-ROS has only been observed in NSCLC (8, 9, 23). Although parallels can be
inferred and new pathways can be discovered from fibroblast expression models of cancer
(as seen in the current study), they often constitute a weak alternative to cancer-specific
derived models. Because there are no established NSCLC cell lines that endogenously
express CD74-ROS, we relied on ectopic expression of CD74-ROS in non-invasive NSCLC
lines to study the effects of CD74-ROS kinase activity on signaling and invasion. Using
three non-invasive NSCLC lines (H1915, H2009 and H1755), we demonstrated that
expression of active CD74-ROS drastically causes these cells to invade and that the invasion
parallels the appearance of E-Syt1 phosphorylation on tyrosine residues. These results are
similar to our earlier observations in fibroblasts and demonstrate that in a clinically relevant
context, expression of CD74-ROS induces invasive mechanisms that likely rely on E-Syt1
activity.
Interestingly, ectopic expression of CD74-ROS in established NSCLC tumor cell lines
triggers variable signaling responses. The canonical MAPK, STAT-3 and mTORC1
pathways are utilized to various degrees in these lines, from non-existent to moderate. This
likely result from the fact that the tumors that gave rise to these lines arose under specific
combinations of tumor suppressor genes loss and oncogenes activation (other than CD74-
ROS) and are thus “wired” a certain way. This “wiring” may or may not express signaling
members that are canonical to an ectopically expressed oncoprotein (e.g. CD74-ROS). In
this context ectopic expression of an oncogenic protein (e.g. CD74-ROS) may display
variable signaling responses when presented to different tumor cell lines. One consistent
signaling response to ROS fusion kinase expression however is the activation of SHP-2, a
known oncoprotein, which we observed both in fibroblasts and in all three NSCLC cell
lines. It is therefore likely that the major driving signaling pathway initiated by ROS fusion
kinases is the activation of SHP-2.
Although FIG-ROS and CD74-ROS are equally oncogenic, we discovered that CD74-ROS
expressing cells displayed an invasive and metastatic phenotype over FIG-ROS cells.
Lymph node metastasis is rarely seen in xenograft models, underlying the strength of CD74-
ROS signaling as pro-invasive and metastatic. We surmised that differences in
phosphorylation of downstream targets might be responsible for this observation and a
global quantitative phosphoproteomic screen revealed that the plasma membrane protein E-
Syt1 is 16 times more phosphorylated on Y993 in CD74-ROS expressing cells than in FIG-
ROS cells. By eliminating E-Syt1 expression in CD74-ROS cells the invasive phenotype
was abrogated in vivo and in vitro. This reduction of expression did not affect the activation
of the signaling pathways SHP-2, STAT-3 and MAPK nor did it affect CD74-ROS
oncogenicity. It is conceivable that localization of FIG-ROS to the Golgi membrane
prevents access to E-Syt1, whereas CD74-ROS, a plasma membrane-bound receptor, readily
has access to E-Syt1.
E-Syt1 is a member of the E-Syt family (E-Syt1-3) (24) of membrane proteins structurally
composed of an NH2-terminal transmembrane region, a highly conserved intracellular
juxtamembrane domain and five (E-Syt1) or three (E-Syt2 and E-Syt3) COOH-terminal C2
domains (24, 25). C2 domains are protein modules that generally act as Ca2+- and
phospholipid-binding domains and/or as protein-protein interaction domains (26). E-Syt1 is
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assumed to be an integral plasma membrane protein given its overall architecture although
Min et al., have demonstrated that transiently overexpressed E-Syt1 in HEK293 cells
localizes to endomembranes (24). Regardless of its localization, our results demonstrate that
E-Syt1 is phosphorylated on Y993 in plasma membrane-bound CD74-ROS expressing cells
and not in Golgi apparatus located FIG-ROS expressing cells.
Tyrosine 993 resides within the fifth C2 domain of E-Syt1 and is conserved amongst other
E-Syt family members. The same C2 domain has been demonstrated in E-Syt2 to be
required for E-Syt2 plasma membrane binding (24). It is conceivable that phosphorylation
on Y993 in E-Syt1 may modulate a similar C2-mediated plasma membrane association,
which may be important for the regulation of E-Syt1 function in cancer cell invasion.
Phosphorylation of E-Syt1 on tyrosine sites has been observed in various cancers.
Phosphorylation on Y832 has been detected in breast cancer MCF-10A cells expressing
CSF-1R (27), in PYK2 expressing NIH-3T3 cells (28), in stomach cancer MKN-45 cells
treated with the MET inhibitor SU-11274 (29, 30) and the NSCLC cells H3255 treated with
gefitinib (29, 30) and H1703 treated with imatinib (30). It has also been detected in human
mammary epithelial cell (HMEC) (31) and Jurkat cells (32). Phosphorylation of E-Syt1 on
Y1019 (homologue of Y993 in rat) has also been detected in 32D cells expressing both
plasma membrane and endoplasmic reticulum bound activated Flt3 RTK (33), in MKN-45
cells (29) and in numerous NSCLC human biosamples (23). It is unlikely that CD74-ROS is
present in all those different cancer cell types and biosamples, suggesting that alternative
events can promote the phosphorylation of E-Syt1. Our results suggest that phosphorylated
E-Syt1 may confer invasiveness and metastatic potential to cancer cells and offer a new
therapeutic strategy against cancer cell invasion and metastasis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ROS fusion kinases are oncogenic. A, schematic representation of the ROS fusion kinases
used in this study. The numbering refers to the amino acid position for the indicated
domains of the fusion proteins. All constructs are Myc epitope tagged. B, growth curves of
ROS fusion kinases expressing Rat1 clones. For each indicated ROS fusion construct,
results from three independent clones are averaged and plotted as the mean ± S.D.
Representative photographs of Rat1 cells expressing the indicated ROS fusion kinase
variants in (C) focus formation and (D) anchorage-independent growth in soft agar assays.
Quantitation of the focus formation assay is depicted in Supplementary Fig. 1B. E, growth
of the indicated ROS fusion expressing Rat1 clones as subcutaneous xenografts in
immunocompromised mice. 106 Rat1 cells were injected into the flanks of NIHnu/nu mice
and tumors developed within 20–25 days. Mice that did not developed tumors were
observed for a period of 50 days. Kinase-inactive (KM) versions of these ROS fusions
proteins were included as controls. The construct SLC34A2-ROS is abbreviated to SLC-
ROS. Scale bar= 250 μm.
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Cells expressing ROS fusion kinases are sensitive to ALK inhibitors. A, ROS fusion
kinases-expressing Rat1 cells were grown in the presence of NVP-TAE684 to determine
IC50 values. B, western blot analysis of total cell lysates from pooled Rat1 clones of ROS
fusion kinases treated with NVP-TAE684 for 24 hours and probed for the indicated
signaling proteins using phospho-specific antibodies. Blots were stripped and rehybridized
with the indicated antibodies to control for expression levels and loading. (C–E) NVP-
TAE684 reverses ROS fusion kinase-expressing Rat1 cells transformed phenotype. Cells
were treated with NVP-TAE684 (10 nM) or vehicle and assayed for (C) saturation density
growth inhibition, (D) focus formation and (E) growth in soft agar. Quantitation of the focus
formation assay is depicted in Supplementary Fig. 4B.
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CD74-ROS expressing cells are highly invasive and metastatic. (A, B) Representative
photomicrographs of H&E stained paraffin embedded cross sections of subcutaneous
xenograft tumors from clonal FIG-ROS and CD74-ROS expressing Rat1 cells. Arrows point
to invasive areas. Stars mark the locations of ribs. T; tumor, LN; lymph node. Scale bars:
(A) 500 μm (B) 250 μm. C, graphical representation of CD74-ROS invasiveness as
measured by in vitro Boyden chamber matrigel invasion assays.
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Quantitative phosphotyrosine profiling reveals significant differences between FIG-ROS
and CD74-ROS expressing Rat1 cells. A, thirty five tyrosine phosphorylated peptides that
were found to have significantly different (p=≤0.05) levels between FIG-ROS and CD74-
ROS expressing cells are represented in a heat map. Peptides were sorted based on the
relative iTRAQ ratios found in CD74-ROS relative to the mean. Protein names are
abbreviated and phosphorylation site numbering is based on that present in phosphosite.
SLC34A2-(S)ROS expressing cells are abbreviated as SLC-ROS. Ratios shown on the axis
refer to iTRAQ ratios relative to the mean. B, bar chart depicting the relative iTRAQ ratios
across 3 biological replicates. Error bars are representative of the standard deviation. FIG-
ROS-WT and CD74-ROS-WT ratios are significantly different based on students t-test. *
p=2.07 e−5. C, a representative manually validated tandem MS spectrum of E-SYT1 peptide
DLPDPYVSVLLLPDK indicating the presence of phosphorylation site pY993 (mascot
score; 37). D, lysates from parental Rat1 cells (pLXSN vector control), FIG-ROS and
CD74-ROS expressing cells were immunoprecipitated (IP) with either E-Syt1 or anti
phosphotyrosine antibodies. The immunoprecipitates were analyzed for phosphotyrosine
content (pTyr) or for the presence of E-Syt1 protein respectively by immunoblotting (IB).
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E-SYT1 is a driver of invasion. A, western blot analysis of E-Syt1 expression knock down
from control pLXSN, FIG-ROS and CD74-ROS expressing Rat1 cells using a scrambled
control and two short hairpin RNAs. B, graphical representation of the in vitro invasiveness
of parental CD74-ROS expressing Rat1 cells and E-Syt1 shRNA knock down clones and
controls. C, elimination of E-Syt1 expression in CD74-ROS Rat1 cells abolishes invasion in
vivo. Arrows point to invasive areas. Stars mark the locations of ribs. T; tumor. Scale bar:
500 μm.
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Expression of CD74-ROS in NSCLC cells induces invasion and E-Syt1 phosphorylation. A,
cell lysates from the indicated NSCLC cell lines expressing CD74-ROS-WT or CD74-ROS-
KM fusion proteins were immunoblotted for expression levels (9E10) and
immunoprecipitated (IP) with an anti phosphotyrosine antibody and analyzed for the
presence of E-Syt1 protein by immunoblotting (IB). B, graphical representation of in vitro
invasion of NSCLC cell lines expressing CD74-ROS-WT or CD74-ROS-KM fusion
proteins. The data is shown as fold increase in invasion when compared to empty pLXSN
vector controls for the respective lines and is calculated using three independent clones for
each construct.
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Expression of CD74-ROS in NSCLC cells induces SHP-2 signaling. Immunoblot analysis of
total cell lysates from pools of three independent NSCLC clones from each of the NSCLC
cell lines probed for the indicated proteins using phospho-specific antibodies. A, activation
of the tyrosine phosphatase SHP-2 and the mTORC1 pathways. B, the STAT-3 and MAPK
pathways. All blots were stripped and rehybridized with the indicated antibodies to control
for expression levels and loading.
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